Nephro-Urology Monthly

Published by: Kowsar

Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient

Simin Dashti-Khavidaki 1 , * , Lida Shojaie 2 , Amin Hosni 2 , Mohammad Reza Khatami 1 and Atefeh Jafari 2
Authors Information
1 Nephrology Research Center, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Article information
  • Nephro-Urology Monthly: May 01, 2015, 7 (3); e27073
  • Published Online: May 23, 2015
  • Article Type: Research Article
  • Received: January 17, 2015
  • Accepted: February 9, 2015
  • DOI: 10.5812/numonthly.7(3)2015.27073

To Cite: Dashti-Khavidaki S, Shojaie L, Hosni A, Khatami M R, Jafari A. Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient, Nephro-Urol Mon. 2015 ; 7(3):e27073. doi: 10.5812/numonthly.7(3)2015.27073.

Abstract
Copyright © 2015, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
References
  • 1. Levine MH, Abt PL. Treatment options and strategies for antibody mediated rejection after renal transplantation. Semin Immunol. 2012; 24(2): 136-42[DOI][PubMed]
  • 2. Lefaucheur C, Loupy A, Vernerey D, Duong-Van-Huyen JP, Suberbielle C, Anglicheau D, et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet. 2013; 381(9863): 313-9[DOI][PubMed]
  • 3. Barba J, Zudaire JJ, Robles JE, Rosell D, Berian JM, Pascual I. Complications of kidney transplantation with grafts from expanded criteria donors. World J Urol. 2013; 31(4): 893-900[DOI][PubMed]
  • 4. Amer H, Sibulesky L, Wadei HM. Complications of Kidney Transplantation. 2013; [DOI]
  • 5. White NB, Greenstein SM, Cantafio AW, Schechner R, Glicklich D, McDonough P, et al. Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation. 2004; 78(5): 772-4[PubMed]
  • 6. Djamali A, Kaufman DB, Ellis TM, Zhong W, Matas A, Samaniego M. Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant. 2014; 14(2): 255-71[DOI][PubMed]
  • 7. Schinstock C, Stegall MD. Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management. Curr Transplant Rep. 2014; 1(2): 78-85
  • 8. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol. 2007; 18(4): 1046-56[DOI][PubMed]
  • 9. John R, Herzenberg AM. Our approach to a renal transplant biopsy. J Clin Pathol. 2010; 63(1): 26-37[DOI][PubMed]
  • 10. Gloor JM, Winters JL, Cornell LD, Fix LA, DeGoey SR, Knauer RM, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant. 2010; 10(3): 582-9[PubMed]
  • 11. Kim M, Martin ST, Townsend KR, Gabardi S. Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options. Pharmacotherapy. 2014; 34(7): 733-44[DOI][PubMed]
  • 12. Montgomery RA, Cozzi E, West LJ, Warren DS. Humoral immunity and antibody-mediated rejection in solid organ transplantation. Semin Immunol. 2011; 23(4): 224-34[DOI][PubMed]
  • 13. Roberts DM, Jiang SH, Chadban SJ. The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. Transplantation. 2012; 94(8): 775-83[DOI][PubMed]
  • 14. Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost. 2013; 11(3): 481-90[DOI][PubMed]
  • 15. Ireland R. Thrombotic microangiopathy: rituximab in severe autoimmune TTP. Nat Rev Nephrol. 2012; 8(3): 131[DOI][PubMed]
  • 16. Clark WF. Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange. Semin Dial. 2012; 25(2): 214-9[PubMed]
  • 17. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014; 371(7): 654-66[DOI][PubMed]
  • 18. Froissart A, Buffet M, Veyradier A, Poullin P, Provot F, Malot S, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012; 40(1): 104-11[DOI][PubMed]
  • 19. Kremer Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010; 115(8): 1500-11[DOI][PubMed]
  • 20. Noris M, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Transplant. 2010; 10(7): 1517-23[PubMed]
  • 21. Jodele S, Laskin BL, Goebel J, Khoury JC, Pinkard SL, Carey PM, et al. Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy? Transfusion. 2013; 53(3): 661-7[PubMed]
  • 22. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001; 345(10): 747-55[DOI][PubMed]
  • 23. Frank MM, Miletic VD, Jiang H. Immunoglobulin in the Control of Complement Action. Immunol Res. 2000; 22(2-3): 137-46
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments